Premium
Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation
Author(s) -
Xu Su,
Jordan E. Kay,
Brocke Stefan,
Bulte Jeff W.M.,
Quigley Laura,
Tresser Nancy,
Ostuni John L.,
Yang Yihong,
McFarland Henry F.,
Frank Joseph A.
Publication year - 1998
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/(sici)1097-4547(19980601)52:5<549::aid-jnr7>3.0.co;2-c
Subject(s) - multiple sclerosis , encephalomyelitis , medicine , pathology , in vivo , histopathology , lesion , experimental autoimmune encephalomyelitis , magnetic resonance imaging , perivascular space , inflammation , immunology , radiology , biology , microbiology and biotechnology
MION‐46L, a superparamagnetic iron oxide contrast agent, was investigated for its ability to increase the sensitivity of in vivo 3D MRI in the detection of brain lesions in a chronic experimental allergic encephalomyelitis (crEAE) mouse model. Lesion conspicuity on postcontrast 3D MRI was dramatically enhanced as compared to precontrast images corresponding to areas of inflammatory and demyelinating lesions. MION‐46L could be detected on Prussian blue iron stain in the vascular endothelium, the perivascular space, and in macrophages within perivascular cuffs and areas of inflammation and demyelination. By taking advantage of the MION‐46L induced macroscopic susceptibility effect, acute early lesions measuring only 100 μm in diameter could be detected. MION‐46L enhanced MRI may be used to 1) provide a unique sensitivity in EAE lesion detection and correlate imaging to histopathology; 2) help to understand EAE lesion development and its underlying pathophysiology; and 3) eventually assist in preclinical screening of new experimental therapies directed at patients with multiple sclerosis (MS). J. Neurosci. Res. 52:549–558, 1998. Published 1998 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.